Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, McConathy J, Cairns NJ, Fagan AM, Morris JC, Ances BM.

JAMA Neurol. 2016 Sep 1;73(9):1070-7. doi: 10.1001/jamaneurol.2016.2078.

2.

Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.

Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, Benzinger TL.

JAMA Neurol. 2016 Oct 1;73(10):1192-1200. doi: 10.1001/jamaneurol.2016.2642.

3.

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.

JAMA Neurol. 2014 Oct;71(10):1282-9. doi: 10.1001/jamaneurol.2014.1358.

PMID:
25155658
4.

Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.

Buckley RF, Hanseeuw B, Schultz AP, Vannini P, Aghjayan SL, Properzi MJ, Jackson JD, Mormino EC, Rentz DM, Sperling RA, Johnson KA, Amariglio RE.

JAMA Neurol. 2017 Dec 1;74(12):1455-1463. doi: 10.1001/jamaneurol.2017.2216.

5.

Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease.

Wang L, Benzinger TL, Hassenstab J, Blazey T, Owen C, Liu J, Fagan AM, Morris JC, Ances BM.

Neurology. 2015 Mar 24;84(12):1254-60. doi: 10.1212/WNL.0000000000001401. Epub 2015 Feb 25.

6.

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM.

JAMA Neurol. 2015 Sep;72(9):1029-42. doi: 10.1001/jamaneurol.2015.1285.

7.

Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.

Ben Bouallègue F, Mariano-Goulart D, Payoux P; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Alzheimers Res Ther. 2017 Apr 26;9(1):32. doi: 10.1186/s13195-017-0260-z.

8.

Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.

Xia C, Makaretz SJ, Caso C, McGinnis S, Gomperts SN, Sepulcre J, Gomez-Isla T, Hyman BT, Schultz A, Vasdev N, Johnson KA, Dickerson BC.

JAMA Neurol. 2017 Apr 1;74(4):427-436. doi: 10.1001/jamaneurol.2016.5755.

9.

Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals.

Mormino EC, Papp KV, Rentz DM, Schultz AP, LaPoint M, Amariglio R, Hanseeuw B, Marshall GA, Hedden T, Johnson KA, Sperling RA.

JAMA Neurol. 2016 Oct 1;73(10):1185-1191. doi: 10.1001/jamaneurol.2016.2237.

10.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
11.

In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.

Zhao Y, Raichle ME, Wen J, Benzinger TL, Fagan AM, Hassenstab J, Vlassenko AG, Luo J, Cairns NJ, Christensen JJ, Morris JC, Yablonskiy DA.

Neuroimage. 2017 Mar 1;148:296-304. doi: 10.1016/j.neuroimage.2016.12.026. Epub 2016 Dec 15.

12.

PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers.

Koychev I, Gunn RN, Firouzian A, Lawson J, Zamboni G, Ridha B, Sahakian BJ, Rowe JB, Thomas A, Rochester L, Ffytche D, Howard R, Zetterberg H, MacKay C, Lovestone S; Deep and Frequent Phenotyping study team (.

J Alzheimers Dis. 2017;60(1):283-293. doi: 10.3233/JAD-170129.

13.

Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.

Gomperts SN, Locascio JJ, Makaretz SJ, Schultz A, Caso C, Vasdev N, Sperling R, Growdon JH, Dickerson BC, Johnson K.

JAMA Neurol. 2016 Nov 1;73(11):1334-1341. doi: 10.1001/jamaneurol.2016.3338.

14.

The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.

Niemantsverdriet E, Ottoy J, Somers C, De Roeck E, Struyfs H, Soetewey F, Verhaeghe J, Van den Bossche T, Van Mossevelde S, Goeman J, De Deyn PP, Mariën P, Versijpt J, Sleegers K, Van Broeckhoven C, Wyffels L, Albert A, Ceyssens S, Stroobants S, Staelens S, Bjerke M, Engelborghs S.

J Alzheimers Dis. 2017;60(2):561-576. doi: 10.3233/JAD-170327.

15.

Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.

Schreiber S, Schreiber F, Lockhart SN, Horng A, Bejanin A, Landau SM, Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2017 Jun 1;74(6):650-659. doi: 10.1001/jamaneurol.2016.5349.

16.

Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.

Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, Rabinovici GD, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2017 Aug 15;157:448-463. doi: 10.1016/j.neuroimage.2017.05.058. Epub 2017 Jun 3.

17.

Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.

Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S.

Arch Neurol. 2009 May;66(5):632-7. doi: 10.1001/archneurol.2009.59.

18.

AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure.

Mishra S, Gordon BA, Su Y, Christensen J, Friedrichsen K, Jackson K, Hornbeck R, Balota DA, Cairns NJ, Morris JC, Ances BM, Benzinger TLS.

Neuroimage. 2017 Nov 1;161:171-178. doi: 10.1016/j.neuroimage.2017.07.050. Epub 2017 Jul 26.

PMID:
28756238
19.

Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.

Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, Morris JC, Holtzman DM.

JAMA Neurol. 2015 Jun;72(6):656-65. doi: 10.1001/jamaneurol.2015.0202.

20.

Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia.

Knopman DS, Jack CR Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Machulda MM, Roberts RO, Boeve BF, Jones DT, Petersen RC.

Neurology. 2016 Aug 16;87(7):691-8. doi: 10.1212/WNL.0000000000002979. Epub 2016 Jul 15.

Supplemental Content

Support Center